axitinib,sunitinib,pembrolizumab,cabozantinib,nivolumab,ipilimumab,Lenvatinib
bms,merck,pfizer
['check,mate,214', 'rcc,(-irccs),(-srcc),(-urcc)', 'key,note,426', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'check,mate,9er']
2023 updates to first line metastatic rcc trials (in the itt populations) from #gu23 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday